BTLA and neoplasm: Experimental BTLA blockade in B cells, either via genetic deletion or monoclonal antibodies, has been reported to enhance antigen-specific antibody responses and increase the ability of B cells to prime CD4+ T cells in preclinical tumor models [27,112].